Recombinant Human CYP3A4 protein, MYC/DDK-tagged
Cat.No. : | CYP3A4-18H |
Product Overview : | Recombinant Human CYP3A4 fused with MYC/DDK tag at C-terminal was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Human |
Tag : | MYC/DDK |
Form : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Publication : |
Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers (2018)
|
Gene Name : | CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 [ Homo sapiens ] |
Official Symbol : | CYP3A4 |
Synonyms : | CYP3A4; cytochrome P450, family 3, subfamily A, polypeptide 4; CYP3A3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4; cytochrome P450 3A4; nifedipine oxidase; cytochrome P450 3A3; cytochrome P450 HLp; cytochrome P450-PCN1; cytochrome P450 NF-25; albendazole sulfoxidase; quinine 3-monooxygenase; albendazole monooxygenase; P450-III, steroid inducible; glucocorticoid-inducible P450; taurochenodeoxycholate 6-alpha-hydroxylase; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4; HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1; MGC126680; |
Gene ID : | 1576 |
mRNA Refseq : | NM_017460 |
Protein Refseq : | NP_059488 |
MIM : | 124010 |
UniProt ID : | P08684 |
Chromosome Location : | 7q21.1 |
Pathway : | Bile secretion, organism-specific biosystem; Bile secretion, conserved biosystem; Biological oxidations, organism-specific biosystem; Codeine and morphine metabolism, organism-specific biosystem; Cytochrome P450 - arranged by substrate type, organism-specific biosystem; Drug metabolism - cytochrome P450, organism-specific biosystem; Drug metabolism - cytochrome P450, conserved biosystem; |
Function : | albendazole monooxygenase activity; caffeine oxidase activity; electron carrier activity; enzyme binding; heme binding; iron ion binding; metal ion binding; monooxygenase activity; monooxygenase activity; oxidoreductase activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; oxygen binding; quinine 3-monooxygenase activity; steroid binding; steroid hydroxylase activity; taurochenodeoxycholate 6alpha-hydroxylase activity; testosterone 6-beta-hydroxylase activity; vitamin D 24-hydroxylase activity; vitamin D3 25-hydroxylase activity; |
Products Types
◆ Recombinant Protein | ||
CYP3A4-81H | Active Recombinant Human CYP3A4 Protein | +Inquiry |
CYP3A4-2273H | Recombinant Human CYP3A4 Protein, GST-tagged | +Inquiry |
CYP3A4-983R | Recombinant Rhesus Macaque CYP3A4 Protein, His (Fc)-Avi-tagged | +Inquiry |
CYP3A4-347H | Active Recombinant Human CYP3A4 Protein | +Inquiry |
CYP3A4-1301H | Recombinant Human CYP3A4 Protein, His-tagged | +Inquiry |
◆ Lysates | ||
CYP3A4-436HCL | Recombinant Human CYP3A4 cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-1918 | Cytochrome P450 3A4 (CYP3A4) Activity Assay Kit | +Inquiry |
Kit-2142 | Cytochrome P450 3A4 Inhibitor Screening Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionVariability in CYP3A4 activity due to genetic, environmental, and health factors results in diverse drug responses among individuals.
CYP3A4 inhibitors can increase, while inducers can decrease drug levels, affecting their safety and effectiveness.
CYP3A4 is predominantly expressed in the liver and intestines.
CYP3A4 is crucial for breaking down and clearing a wide variety of drugs and toxins from the body.
Genetic polymorphisms in CYP3A4 can result in altered enzyme activity, impacting drug metabolism.
Managing CYP3A4-mediated interactions may involve using drug interaction databases, adjusting drug dosages, or choosing alternative medications.
CYP3A4 activity is generally lower in infants, peaks in childhood, and varies in adults.
Customer Reviews (3)
Write a reviewSuperior quality, highly recommend.
Worked well, as described.
Perfect for protein studies.
Ask a Question for All CYP3A4 Products
Required fields are marked with *
My Review for All CYP3A4 Products
Required fields are marked with *
Inquiry Basket